A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: August 22, 2006
Last updated: June 22, 2011
Last verified: June 2011
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial

Condition Intervention Phase
HIV Infection
Drug: apricitabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Long Term Safety Extension Study of Apricitabine in Treatment-experienced HIV-1 Infected Subjects

Resource links provided by NLM:

Further study details as provided by Avexa:

Primary Outcome Measures:
  • Time to virological failure (DHSS definition) [ Time Frame: week 144 ] [ Designated as safety issue: No ]
  • incidence of AEs and laboratory abnormalities [ Time Frame: Week 144 ] [ Designated as safety issue: Yes ]
  • time to withdrawal due to AEs [ Time Frame: Week 144 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change from baseline HIV RNA [ Time Frame: weeks 72, 96, 120, and 144 ] [ Designated as safety issue: No ]
  • Proportion of subjects with plasma HIV RNA <400 and <50 copies/ml [ Time Frame: at weeks 72, 96, 120, and 144 ] [ Designated as safety issue: No ]
  • Change from baseline and change in ratio of CD4+ and CD8+ counts [ Time Frame: at weeks 72, 96, 120, and 144 ] [ Designated as safety issue: No ]

Enrollment: 42
Study Start Date: August 2006
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ATC 800mg BID
800mg ATC BID
Drug: apricitabine
800mg apricitabine twice daily orally for 96 weeks

Detailed Description:

An ongoing study (AVX-201) is examining the safety and efficacy of apricitabine compared to 3TC in HIV patients who are failing therapy containing 3TC and have the presence of the M184V mutation in reverse transcriptase. This extension study (AVX-201E) is available to patients who complete the AVX-201 protocol.

Patients will continue to receive apricitabine open label for a further 96 weeks (making a total of 144 weeks from starting AVX-201) in addition to an optimised background. Safety markers and efficacy markers will be followed.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed AVX-201 protocol, Plasma HIV RNA <5000 copies/ml, CD4 cells >50

Exclusion Criteria:

  • Pregnant or breastfeeding females, withdrawal from AVX-201
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00367952

Australia, Victoria
Avexa (co-ordinating sites in Australia and Argentina)
Melbourne, Victoria, Australia, 3121
Sponsors and Collaborators
Study Director: Susan W Cox, Ph D Avexa
  More Information

Responsible Party: Susan Cox, Avexa
ClinicalTrials.gov Identifier: NCT00367952     History of Changes
Other Study ID Numbers: AVX-201E 
Study First Received: August 22, 2006
Last Updated: June 22, 2011
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica

Keywords provided by Avexa:
drug resistance
reverse transcriptase

ClinicalTrials.gov processed this record on May 30, 2016